Oxford Biomedica Regulatory News (OXB)

Oxford BioMedica Announces Stuart Henderson Appointed as a Non-Executive Director

London, UK - 26 April 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE:OXB), a leading gene and cell therapy company, today announces the appointment of Stuart Henderson as a non-executive Director of the Company and Chair of the Audit Committee with effect from 1 June 2016.

Mr Henderson joins Oxford BioMedica from Deloitte, where he was Head of European Healthcare and Life Sciences and also served on the Global Industry Team for seven years between 2004 and 2011. Prior to this he was Partner at Arthur Andersen from 1982 to 2002, where he sat on the Andersen Global Life Sciences Team as Head of Emerging Biotechnology.

Mr Henderson has extensive experience in audit and transaction support practice and has worked with life science businesses from start up to multinational as well as acting as reporting accountant on numerous IPO and Class 1 transactions. He has reported as Audit Partner to the audit committees of publicly quoted companies for over 20 years.

Mr Henderson is a former director of the Babraham Institute and currently sits as an observer on the board of OneNucleus, the Life Sciences trade body for Cambridge and London.

Lorenzo Tallarigo, Chairman of Oxford BioMedica, commented: "We welcome Stuart to the Board and look forward to working with him at this exciting time for the Oxford BioMedica. Stuart's extensive experience as an advisor to companies in the healthcare sector accrued throughout his distinguished career will no doubt prove invaluable as we continue to progress towards the next phase of the Company's growth." 

There are no further disclosures required pursuant to LR 9.6.13R of the Listing Rules of the UK Listing Authority in relation to his appointment.

- Ends -

Notes for editors

About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people. Further information is available at www.oxfordbiomedica.co.uk.